Search
Prazosin
go.drugbank.com/drugs/DB00457ApprovedInvestigationalPrazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists. … Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.[A176618, A176621, A176624]
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigational[A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323] … Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease.
Buserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalIt is used in prostate cancer treatment.
Bleomycin
go.drugbank.com/drugs/DB00290ApprovedInvestigationalIt inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Hemoglobin
go.drugbank.com/drugs/DB04945ApprovedInvestigationalWithdrawnThe respiratory protein of the red blood cells. It consists primarily of globin and heme.
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Proflavine
go.drugbank.com/drugs/DB01123ApprovedInvestigationalTopical antiseptic used mainly in wound dressings.
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[L40026] It received subsequent approval for the same indications in Canada in May 2022. … [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026]
Calcium glubionate anhydrous
go.drugbank.com/drugs/DB13142ApprovedCalcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.